Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands

Autoimmunity

Volumn 40, Issue 7, 2007, Pages 497-502

  Tsuzaka, Kensei ^a,b   Matsumoto, Yukihiro ^c   Sasaki, Yasumasa ^c   Abe, Tohru ^a   Tsubota, Kazuo ^c   Takeuchi, Tsutomu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Autoimmune lymphoproliferative syndrome; Autoimmunity; Sj gren's syndrome

Indexed keywords

BETA GALACTOSIDASE; CYTOSINE; FAS LIGAND; MESSENGER RNA; MUTANT PROTEIN; THYMINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE VECTOR; HETEROZYGOSITY; HUMAN; HUMAN CELL; LACRIMAL GLAND; LUMINESCENCE; LYMPHOCYTE PROLIFERATION; MIKULICZ DISEASE; MOLECULAR MECHANICS; PERIPHERAL LYMPHOCYTE; POINT MUTATION; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SJOEGREN SYNDROME; TRANSCRIPTION REGULATION; WILD TYPE;

BLOOD CELLS; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; LACRIMAL APPARATUS; MALE; MIKULICZ' DISEASE; POINT MUTATION; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SJOGREN'S SYNDROME; TRANSCRIPTION, GENETIC;

EID: 39049127459     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930701580320     Document Type: Article

References (22)

1. Fox, RI (1994) Epidemiology, pathogenesis, animal models, and treatment of Sjogren's syndrome. Curr Opin Rheumatol, 6, pp. 501-508.
2. Kong, L., Ogawa, N., Nakabayashi, T., Liu, GT, D'Souza, E., McGuff, HS, Guerrero, D., Talal, N. and Dang, H. (1997) Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum, 40, pp. 87-97.
3. 7T cells around acinar epithelial cells with apoptosis in patients with Sjögren's syndrome. J Immunol, 163, pp. 2226-2235.
4. Schaffer, A. and Jacobsen, A. (1927) Mikulicz's syndrome: A report of ten cases. Am J Dis Child, 34, pp. 327-346.
5. Tsubota, K., Fujita, H., Tsuzaka, K. and Takeuchi, T. (2000) Mikulicz's disease and Sjögren's syndrome. Invest Ophthalmol Vis Sci, 41, pp. 1666-1673.
6. Tsubota, K., Fujita, H., Tadano, K., Onoda, N., Tsuzaka, K. and Takeuchi, T. (2002) Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands. Clin Exp Immunol, 129, pp. 177-182.
7. Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, HM, Alexander, EL, Carsons, SE, Daniels, TE, Fox, PC, Fox, RI, Kassan, SS, Pillemer, SR, Talal, N. and Weisman, MH (2002) Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis, 61, pp. 554-558.
8. Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T. and Nagata, S. (1994) Human Fas ligand: Gene structure, chromosomal location and species specificity. Int Immunol, 6, pp. 1567-1574.
9. Tsuzaka, K., Nozaki, K., Kumazawa, C., Shiraishi, K., Setoyama, Y., Yoshimoto, K., Suzuki, K., Abe, T. and Takeuchi, T. (2006) DNA microarray gene expression profile of T cells with the splice variants of TCRζ mRNA observed in SLE. J Immunol, 176, pp. 949-956.
10. Chen, JY, Wang, CM, Ma, CC, Chow, YH and Luo, SF (2005) The - 844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE. Genes Immun, 6, pp. 123-128.
11. Wu, J., Metz, C., Xu, X., Abe, R., Gibson, AW, Edberg, JC, Cooke, J., Xie, F., Cooper, GS and Kimberly, RP (2003) A novel polymorphic CAAT/ enhancer-binding protein element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol, 70, pp. 132-138.
12. Fernandez, RM, Noval, JA, Garcia-Lozano, JC, Borrego, S., Molini, JL and Antinolo, G. (2005) Polymorphisms in the promoter regions of FAS and FASL genes as candidate genetic factors conferring susceptibility to endometriosis. Int J Mol Med, 15, pp. 865-869.
13. Gormus, U., Ergen, A., Yilmaz, H., Dalan, B., Berkman, S. and Isbir, T. (2007) Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res, 27, pp. 991-994.
14. Li, C., Wu, W., Liu, J., Qian, L., Li, A., Yang, K., Wei, Q., Zhou, J. and Zhang, Z. (2006) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: A case-control analysis. Pharmacogenet Genomics, 16, pp. 245-251.
15. Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y. and Lin, D. (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet, 42, pp. 479-484.
16. Kavurma, MM, Santiago, FS, Bonfoco, E. and Khachigian, LM (2001) Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem, 276, pp. 4964-4971.
17. Kavurma, MM, Bobryshev, Y. and Khachigian, LM (2002) Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1. J Biol Chem, 277, pp. 36244-36252.
18. Rieux-Laucat, F., Deist, F Le, Hivroz, C., Roberts, IA, Debatin, KM, Fischer, A. and de Villartay, JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 268, pp. 1347-1349.
19. Fisher, GH, Rosenberg, FJ, Straus, SE, Dale, JK, Middleton, LA, Lin, AY, Strober, W., Lenardo, MJ and Puck, JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell, 81, pp. 935-946.
20. Drappa, J., Vaishnaw, AK, Sullivan, KE, Chu, JL and Elkon, KB (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med, 335, pp. 1643-1649.
21. Deist, F Le, Emile, JF, Rieux-Laucat, F., Benkerrou, M., Roberts, I., Brousse, N. and Fischer, A. (1996) Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet, 348, pp. 719-723.
22. Wu, J., Wilson, J., He, J., Xiang, L., Schur, PH and Mountz, JD (1996) Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest, 98, pp. 1107-1113.